A Phase 3 interventional study of GZR18 injection and Placebo in Overweight or Obesity, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.
Among the 15 studies testing bofanglutide in Obesity, this one is the 7th largest by enrollment, is one of 4 that started in 2026, is one of 5 in phase 3, and was the 12th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Carnot Laboratories · Sites in Mexico
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 5
First in 2021; this study’s year is marked. 4 started in 2026.
This study's enrollment of 224 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 140 across the 15 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 3 most frequent:
This study is registered under Gan & Lee Pharmaceuticals., one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.
15 studies in Obesity by Gan & Lee Pharmaceuticals: 3 open now, 3 under way, 2 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, this one is the 6th largest by enrollment, is one of 4 that started in 2026, is one of 4 in phase 3, and was the 12th registered.
Gan & Lee Pharmaceuticals’s Obesity studies by the year they started, since 2021.
2 of the studies testing bofanglutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150975Phase 3Gan & Lee Pharmaceuticals.Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | 2027-06-30 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing bofanglutide in Obesity, from their registry updates:
Among Gan & Lee Pharmaceuticals’s 15 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight.
In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 224 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to understand the procedures and methods of this study, willing and able to maintain a regular diet and exercise lifestyle during the study period, willing and able to undergo subcutaneous injections of the medicinal product (IMP), and willing to sign the ICF voluntarily.
-
Exclusion Criteria:
Subjects with any other factors (including but not limited to previous compliance in the original study) that may affect the efficacy or safety evaluation of this study as judged by the investigator.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo
Drug: GZR18 injection
Drug: GZR18 injection
Drug: GZR18 injection
Used as specified in the protocol
Administered the same volume as GZR18
Percent change (%) from baseline in body weight
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in weight;
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline body mass index (BMI);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in waist circumference, hip circumference, and waist-hip ratio (waist circumference/hip circumference);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in hemoglobin A1c (HbA1c) ;
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in fasting plasma glucose (FPG);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in blood pressure (SBP and DBP);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in total cholesterol (TC);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in low-density lipoprotein cholesterol (LDL-C);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in high-density lipoprotein cholesterol (HDL-C);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in triglyceride (TG);
Time frame: from Week 0 (W0) to Week 24 (W24)
Changes from baseline in free fatty acids.
Time frame: from Week 0 (W0) to Week 24 (W24)
Treatment-Emergent Adverse Events (TEAEs);
Time frame: from Week 0 (W0) to Week 25 (W25)
Treatment-Emergent Serious Adverse Events (TESAEs);
Time frame: from Week 0 (W0) to Week 25 (W25)
Pulse rate;
Time frame: from Week 0 (W0) to Week 25 (W25)
Lipase;
Time frame: from Week 0 (W0) to Week 25 (W25)
Amylase;
Time frame: from Week 0 (W0) to Week 25 (W25)
Calcitonin
Time frame: from Week 0 (W0) to Week 25 (W25)
The scores of Patient Health Questionnaire-9
the highest/worst score during the trial (the higher scores mean a worse outcome
Time frame: from Week 0 (W0) to Week 25 (W25)
GZR18 anti-drug antibody (ADA) and neutralizing antibody (NAb);
Time frame: from Week 0 (W0) to Week 25 (W25)
Cross reaction between GZR18 ADA and endogenous glucagon-like peptide-1 (GLP-1).
Time frame: from Week 0 (W0) to Week 25 (W25)
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 8 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Sep 2027 → Sep 2026 and completion Oct 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bofanglutide